Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTXNASDAQ:BIMINASDAQ:MEDSNASDAQ:NDRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10$0.08$0.01▼$0.72N/A1.271.32 million shs231,126 shsBIMIBIMI$0.00$0.00$0.00▼$1.65$1K-0.562,781 shs1,000 shsMEDSTRxADE HEALTH$0.91-8.4%$0.94$3.69▼$44.56$1.28M2.32207,831 shs143,864 shsNDRAENDRA Life Sciences$3.19-0.6%$3.82$2.90▼$210.00$2.36M-0.21141,742 shs82,578 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%0.00%BIMIBIMI0.00%-66.67%-66.67%-50.00%-99.99%MEDSTRxADE HEALTH0.00%-14.79%+1.26%-54.66%-89.99%NDRAENDRA Life Sciences0.00%-7.54%+2.57%-28.95%-99.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/ABIMIBIMIN/AN/AN/AN/AN/AN/AN/AN/AMEDSTRxADE HEALTHN/AN/AN/AN/AN/AN/AN/AN/ANDRAENDRA Life Sciences2.9472 of 5 stars3.54.00.00.02.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyx 0.00N/AN/AN/ABIMIBIMI 0.00N/AN/AN/AMEDSTRxADE HEALTH 0.00N/AN/AN/ANDRAENDRA Life Sciences 3.00Buy$50.001,467.40% UpsideCurrent Analyst Ratings BreakdownLatest BIMI, MEDS, APTX, and NDRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025NDRAENDRA Life SciencesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $50.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/ABIMIBIMI$12.63M0.00N/AN/AN/A∞MEDSTRxADE HEALTH$7.45M0.17N/AN/A$0.45 per share2.03NDRAENDRA Life SciencesN/AN/AN/AN/A$4.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/ABIMIBIMI-$22.39MN/A0.00∞N/AN/AN/AN/AN/AMEDSTRxADE HEALTH-$17.84MN/A0.00∞N/A-149.81%-196.79%-112.21%6/24/2025 (Estimated)NDRAENDRA Life Sciences-$11.51M-$172.04N/AN/AN/AN/A-140.96%-106.14%8/13/2025 (Estimated)Latest BIMI, MEDS, APTX, and NDRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024NDRAENDRA Life Sciences-$4.10-$9.40-$5.30-$20.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/ABIMIBIMIN/AN/AN/AN/AN/AMEDSTRxADE HEALTHN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/ABIMIBIMIN/AN/AN/AMEDSTRxADE HEALTHN/A4.184.18NDRAENDRA Life SciencesN/A3.853.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/ABIMIBIMI0.11%MEDSTRxADE HEALTH5.68%NDRAENDRA Life Sciences1.19%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%BIMIBIMI69.02%MEDSTRxADE HEALTH48.40%NDRAENDRA Life Sciences0.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableBIMIBIMI52011.59 million3.59 millionNot OptionableMEDSTRxADE HEALTH501.41 million725,000Not OptionableNDRAENDRA Life Sciences20740,000738,000Not OptionableBIMI, MEDS, APTX, and NDRA HeadlinesRecent News About These CompaniesENDRA’s Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold StandardJune 16, 2025 | finance.yahoo.comENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | businesswire.comENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business UpdateMarch 31, 2025 | finance.yahoo.comENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 TherapiesMarch 31, 2025 | businesswire.comENDRA Life Sciences Inc Registered Shs NDRAFebruary 2, 2025 | morningstar.comWhat Makes ENDRA Life Sciences (NDRA) a New Strong Buy StockJanuary 28, 2025 | zacks.comENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price RequirementNovember 22, 2024 | businesswire.comENDRA Life Sciences Reports Q3 2024 Results and ProgressNovember 16, 2024 | markets.businessinsider.comENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 15, 2024 | finance.yahoo.comStudy Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024November 12, 2024 | finance.yahoo.comENDRA Life Sciences Inc trading halted, news pendingNovember 7, 2024 | markets.businessinsider.comENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European PatentNovember 6, 2024 | finance.yahoo.comWave Life Sciences: Pioneering RNA-Editing with Promising Obesity and Cardiovascular InnovationsNovember 4, 2024 | markets.businessinsider.comWave Life Sciences: Pioneering RNA Editing Technology with Promising Therapeutic PipelineOctober 31, 2024 | markets.businessinsider.comWhat’s Driving ENDRA Life Sciences Inc (NDRA) Stock’s 36.45% Surge Over the Past Month?October 28, 2024 | bovnews.comEndra activates TAEUS system to initiate clinical study at LMU in GermanyOctober 23, 2024 | markets.businessinsider.comLife sciences investor Dimension seeks to raise $500M second fundOctober 23, 2024 | endpts.comWhy ENDRA Life Sciences (NDRA) Stock Is Up 140%October 23, 2024 | benzinga.comLife Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual functionOctober 22, 2024 | ophthalmologytimes.comENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in GermanyOctober 22, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIMI, MEDS, APTX, and NDRA Company DescriptionsAptinyx NASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.BIMI NASDAQ:BIMI$0.0001 0.00 (0.00%) As of 06/20/2025 09:30 AM EasternBIMI Holdings Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes varieties of products, including raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services; and operates two private hospitals in China. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BIMI International Medical Inc. and changed its name to BIMI Holdings Inc. in January 2024. BIMI Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.TRxADE HEALTH NASDAQ:MEDS$0.91 -0.08 (-8.40%) As of 06/20/2025TRxADE HEALTH, Inc. operates as a health services information technology (IT) company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement; and designs, develops, owns, and operates a business-to-business web-based marketplace. It also distributes prescription medication, medical devices, and over the counter medication to pharmacies and medical clinics; and offers pricing transparency, purchasing capabilities, and other value-added services, as well as telehealth services. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. was founded in 2010 and is headquartered in Lutz, Florida.ENDRA Life Sciences NASDAQ:NDRA$3.24 +0.03 (+0.81%) As of 06/20/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
